Permira is selling Australia's I-Med Radiology Network, which recently entered the U.S. by acquiring StatRad, to Hong Kong-based multinational conglomerate Jardine Matheson.
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
Last week hospitals owned by three big health systems filed suit against CVS Health. The trio filed separately, but all accuse the corporation of robbing them of funds they’re owed through the federal 340B drug pricing program.
Quorum Health said the move will allow it to save money through tax exemptions and provide its 11 hospitals with access to the 340B Drug Pricing Program. The health system is majority-owned by Goldentree Asset Management.
The change would represent an imperfect but, in many cases, perfectly appropriate way to oversee the technology without crimping its capabilities. So say three thought leaders who are close watchers of medical ethics and technologies.
The intrusion was caused by the compromised credentials of a Hartford HealthCare employee. Data stolen included full names, Medicaid ID numbers and patient treatment details.
The company says the new device was designed to improve image quality, provide additional maneuverability and simplify ablation workflows for electrophysiologists.
Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.
Here’s a big thing to watch for in the wake of the President’s flashy Middle East tour: the AI “acceleration partnership” between the U.S. and the United Arab Emirates.
Permira is selling Australia's I-Med Radiology Network, which recently entered the U.S. by acquiring StatRad, to Hong Kong-based multinational conglomerate Jardine Matheson.
The Bedford, Massachusetts-based company has reportedly been approached about a possible acquisition by competitor Curium Pharma, Bloomberg reported May 22.
